

COMPREHENSIVE MANAGEMENT OF DEPRESSION BEYOND SSRIS: CURRENT PHARMACOLOGICAL AND NON-PHARMACOLOGICAL STRATEGIES

Anitha Sadula*, Usha Rani Peddaboina, Shaheen Begum, Pendyala Meghana, Mudiga Anuradha

Department of Pharmacy, University College of Technology (A), Osmania University, Hyderabad, 500007, Telangana, India.

Article Received: 13 August 2026

Article Review: 03 September 2026

Article Accepted: 23 September 2026

*Corresponding Author: Anitha Sadula

Department of Pharmacy, University College of Technology (A), Osmania University, Hyderabad, 500007, Telangana, India.

DOI: <https://doi.org/10.5281/zenodo.23076374>

How to cite this Article: Anitha Sadula, Usha Rani Peddaboina, Shaheen Begum, Pendyala Meghana, Mudiga Anuradha (2026). COMPREHENSIVE MANAGEMENT OF DEPRESSION BEYOND SSRIS: CURRENT PHARMACOLOGICAL AND NON-PHARMACOLOGICAL STRATEGIES. World Journal of Pharmacy and Medical Science, 2(10): 81-92.



Copyright © 2026 Anitha Sadula | World Journal of Pharmacy and Medical Science

This is an open-access article distributed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0)

ABSTRACT

Major depressive disorder (MDD) is a globally debilitating condition. While Selective Serotonin Reuptake Inhibitors (SSRIs) are the standard first-line pharmacological treatment, they are limited by delayed onset, adverse effects like emotional blunting, and inadequate efficacy, with up to half of adults failing to achieve remission on their first trial. This review evaluates comprehensive MDD management strategies beyond traditional SSRIs, synthesizing evidence on novel pharmacology, non-pharmacological interventions, and precision medicine. Advanced pharmacological strategies overcome SSRI limitations using novel mechanisms. Multimodal antidepressants like vortioxetine modulate multiple serotonin receptors to enhance efficacy, particularly for cognitive symptoms. Rapid-acting glutamatergic modulators, including esketamine and dextromethorphan-bupropion, provide swift relief for treatment-resistant depression. Furthermore, neurosteroids such as zuranolone and brexanolone offer targeted, rapid treatments specifically for postpartum depression. Beyond pharmacotherapy, comprehensive care relies heavily on non-pharmacological strategies. Psychotherapies like Cognitive Behavioral Therapy (CBT), combined with lifestyle interventions like exercise, significantly reduce depressive symptoms and prevent relapse. For severe or resistant cases, neuromodulation techniques such as repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT) demonstrate substantial efficacy. Additionally, precision medicine is transforming treatment pathways. Pharmacogenomic (PGx) testing utilizes individual genetic profiles-particularly *CYP2D6* and *CYP2C19* metabolic enzymes-to guide antidepressant selection and dosing, thereby improving remission rates and minimizing adverse events. Integrated collaborative care models further optimize these outcomes by pairing psychiatric expertise with primary care. Managing MDD requires a shift from trial-and-error SSRI monotherapy to a personalized, biopsychosocial model. Integrating novel multimodal agents, rapid-acting therapeutics, neuromodulation, behavioral interventions, and pharmacogenomics maximizes therapeutic success and patient well-being.

KEY WORDS: Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), Premenstrual Dysphoric Disorder (PMDD), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Norepinephrine Dopamine Reuptake Inhibitors (NDRIs), Multimodal Antidepressants / Serotonin Modulators, Selective Progesterone Receptor Modulators (SPRMs).

1. INTRODUCTION

Major Depressive Disorder (MDD) is a highly complex, heterogeneous, and pervasive psychiatric condition.^[1,2,3] Clinically, it is primarily defined by a pervasive low

mood and a markedly diminished interest or loss of pleasure in all or almost all everyday activities (anhedonia), which must be present for a minimum of two consecutive weeks.^[4,5,6]




Fig. 1.1: Screening for eligibility.

Beyond these core affective symptoms, a diagnosis of MDD requires a constellation of cognitive, behavioral, and somatic manifestations. These frequently include significant unintended weight or appetite changes, severe sleep disturbances (such as insomnia or hypersomnia), overwhelming fatigue or loss of energy, psychomotor agitation or retardation, diminished ability to think or concentrate, and recurrent thoughts of death or suicidal ideation.^[5,6,7]

The global burden of MDD is staggering, making it one of the leading causes of non-fatal burden of disease and years lived with disability worldwide.^[8,9] Depression affects approximately 5.0% of the global adult population,^[10] translating to an estimated 264 million to over 350 million individuals worldwide.^[8,9] The condition imposes a massive socioeconomic toll through profound functional impairment, escalating healthcare costs, and severe decreases in workplace productivity.^[6,8,9,11] Tragically, MDD is a major driver of premature mortality, contributing to approximately 700,000 suicide-related deaths each year.^[7] This already critical public health crisis was further exacerbated by the COVID-19 pandemic, which precipitated an estimated 28% increase in MDD cases globally within its first year.^[7]

For several decades, Selective Serotonin Reuptake Inhibitors (SSRIs) have served as the cornerstone and standard first-line pharmacological treatment for depression.^[12,13,14,15] Mechanistically, SSRIs competitively inhibit the presynaptic serotonin transporter (SERT), thereby reducing serotonin reuptake

and increasing extracellular serotonin concentrations within the synaptic cleft.^[16,17] Despite their widespread use and relative safety compared to older tricyclic antidepressants, relying solely on SSRI monotherapy is insufficient for a substantial proportion of patients. Clinical data reveal that up to 50% to 60% of patients fail to achieve an adequate response to their initial SSRI trial,^[8,12,14] and initial remission rates remain disappointingly low, typically hovering between 30% and 37.5%.^[1,3,8]

Furthermore, SSRI therapy is fundamentally limited by a delayed onset of therapeutic action; clinical benefits often take two to six weeks to manifest due to the time required for downstream neuroadaptive and neuroplastic changes to occur.^[17] Tolerability is another major barrier, with adverse effect-driven non-adherence rates estimated between 50% and 75%.^[9] Prominent and distressing side effects include high rates of sexual dysfunction (affecting 30% to 70% of patients)^[17] gastrointestinal disturbances, sleep disruption, weight gain, and "apathy syndrome"-an emotional blunting where patients lose the ability to experience a full spectrum of emotions.^[17] Additionally, the abrupt cessation of these medications carries a high risk of debilitating discontinuation or withdrawal syndromes that can persist for months.^[17,19]

The persistent high rates of treatment-resistant depression, lingering residual symptoms (such as cognitive deficits and negative symptoms), and the significant side effect burden of SSRIs necessitate a profound paradigm shift in how depression is treated.^[13,15] Effective resolution of MDD requires a

comprehensive, highly personalized, and multimodal management strategy.^[20,21] To overcome the limitations of standard SSRIs, clinical practice must expand to incorporate advanced pharmacological agents with distinct mechanisms of action, such as multimodal serotonergic modulators (e.g., vortioxetine), rapid-acting glutamatergic agents (e.g., esketamine), and novel neurosteroids (e.g., brexanolone and zuranolone).^[20]

Simultaneously, biological treatments must be integrated with robust non-pharmacological interventions, including evidence-based psychotherapies (like Cognitive Behavioral Therapy), neuromodulation techniques, and lifestyle/dietary modifications.^[6,8,11,21] Finally, the incorporation of precision medicine-specifically pharmacogenomics (PGx)-is crucial. Utilizing genetic

testing for variants in *CYP2D6*, *CYP2C19*, and *SLC6A4* can effectively guide antidepressant selection and dosing, substantially reduce the trial-and-error prescribing process and mitigate adverse drug events.^[8]

Aim of the Review The aim of this review is to systematically evaluate and synthesize current evidence on the comprehensive management of major depressive disorder beyond standard SSRI monotherapy. It will outline the efficacy, mechanisms, and clinical applications of novel pharmacological agents, explore the integration of behavioral and neuromodulatory interventions, and highlight the transformative potential of precision medicine strategies in achieving sustained remission and restoring patient quality of life.



Fig. 1.2: Global overview of Depression.

2. HYPOTHESES TO EXPLAIN MDD PATHOGENESIS




Fig. 2.1: Hypotheses to explain MDD Pathogenesis.

3. PATHOPHYSIOLOGY OF DEPRESSION




Fig. 3.1: Pathophysiology of Depression.

Major depressive disorder (MDD) is a complex, highly heterogeneous syndrome with a multifactorial pathophysiology^[3,15] Historically grounded in the **monoamine hypothesis**, contemporary neuroscience indicates that depression involves a widespread interplay of neurochemical, structural, immunological, and endocrine alterations.^[6,17]

The Monoamine Hypothesis & Neurotransmitters

The foundational theory of depression centers on a deficiency or imbalance of key monoamine neurotransmitters—**serotonin (5-HT), dopamine, and norepinephrine (noradrenaline)**—in the brain's limbic areas.^[6,15,19]

- **Serotonin:** Synthesized from the amino acid tryptophan by the enzyme tryptophan hydroxylase (TPH), serotonin is critical for regulating mood, sleep, appetite, reward, and cognitive functions.^[4] Depressive states are linked to dysregulation at specific receptor sites (such as 5-HT1A and 5-HT2A) and the serotonin transporter (SERT), which regulates extracellular serotonin clearance.^[15]
- **System Cross-Talk:** Serotonergic neurons intricately connect with GABAergic interneurons, influencing the downstream release of dopamine and norepinephrine, demonstrating that depression involves a complex disruption across interconnected neurotransmitter networks.^[22]
- **Neuroplasticity, Neurogenesis, and Brain Structure** Depression is characterized by an impairment in neuroplasticity and overall neuronal health.
- **Neurotrophic Factors:** A reduction in **Brain-Derived Neurotrophic Factor (BDNF)** and its TrkB receptor signaling impedes neurogenesis, synaptogenesis, and cell survival.^[23]

- **Structural Atrophy:** Chronic stress and depression lead to brain atrophy, most notably a **reduction in hippocampal volume** and a loss of neurons in this region, which is vital for memory formation and emotion regulation.^[10]
 - **Corticolimbic Connectivity:** Abnormalities are prevalent in the communication between emotion-generating regions and cognitive control centers. Patients frequently exhibit hyper-reactivity in the amygdala and insula, combined with impaired top-down inhibition from the prefrontal cortex and anterior cingulate cortex.^[5]
 - **Network Dysfunction:** MDD features disrupted spatiotemporal communication among large-scale resting-state brain networks. Specifically, altered activity in the **Default Mode Network (DMN)**, executive control, and salience networks correlates strongly with depressive rumination and altered cognitive control.^[3]
- Neuroinflammation and Immune Dysregulation**
Depression is increasingly recognized as a systemic inflammatory state.
- **Pro-inflammatory Cytokines:** Patients with MDD frequently exhibit elevated levels of pro-inflammatory cytokines, including **TNF- α , IL-1 β , IL-6, and IFN- γ** , as well as markers like C-reactive protein (CRP).^[25] These cytokines activate central microglia and astrocytes into a pro-inflammatory (M1) phenotype, contributing to a neurotoxic environment in the brain.^[20,28]
 - **The Kynurenine Pathway:** Chronic inflammation upregulates the enzyme indoleamine 2,3-dioxygenase (IDO). This enzyme **diverts tryptophan away from serotonin synthesis** and toward the production of neurotoxic catabolites like kynurenine and quinolinic acid. This process directly

depletes serotonin availability while actively causing neuronal cell death.^[2,28]

- **Oxidative Stress:** Depression is also associated with increased oxidative stress, lipid peroxidation, and cellular energy depletion (e.g., splanchnic hypoxia), which exacerbate neurodegeneration.^[2,26,28]

HPA Axis and the Stress Response System Chronic psychosocial and environmental stress profoundly impacts the **hypothalamic-pituitary-adrenal (HPA) axis** and the sympathetic-adrenal-medullary axis.^[21,29]

- Prolonged stress leads to the excessive secretion of cortisol and other glucocorticoids.^[2,29]
- Over time, this hypercortisolemia induces **glucocorticoid receptor resistance**, disabling the negative feedback loop that normally curbs inflammation. This ultimately weakens the immune response, increases vulnerability to illness, and suppresses hippocampal neurogenesis.^[2,27]

The Brain-Gut-Microbiota Axis Emerging evidence highlights the role of the gastrointestinal system, where **approximately 90% of the body's serotonin is synthesized**.^[2,14] The composition of the gut microbiota and its metabolome (e.g., short-chain fatty acids) interact with the central nervous system across the brain-gut axis.^[14] Dysbiosis and pro-inflammatory diets have been identified as significant biological risk factors for triggering or worsening depressive symptoms.^[2,14]

Hormonal and Endocrine Influences Dramatic fluctuations in **gonadal hormones (estrogen and progesterone)** serve as significant biological triggers, particularly in female-specific presentations like Premenstrual Dysphoric Disorder (PMDD), perinatal depression, and perimenopausal depression.^[21]

- Estrogen exerts widespread regulatory effects on serotonin, dopamine, and BDNF signaling.^[21,30]
- Allopregnanolone, a neuroactive metabolite of progesterone, modulates GABA-A receptors. Altered sensitivity to or fluctuating levels of this neurosteroid are tightly linked to anxiety and depressive states during hormonal transitions.^[21]

Genetic and Epigenetic Vulnerabilities The genetic architecture of depression contributes significantly to a predisposition to the illness. Variants in genes encoding the serotonin transporter (*SLC6A4/5-HTTLPR*), serotonin receptors (*HTR2A*), and metabolic enzymes (e.g., *CYP2D6*) heavily influence neurochemical dynamics.^[12] Furthermore, the cumulative physiological stress of depression is associated with **epigenetic changes and accelerated biological aging**, notably marked by shortened peripheral telomere lengths and increased allostatic load.^[23]

4. DIAGNOSIS AND CLINICAL ASSESSMENT

- The clinical assessment and diagnosis of depression relies on structured frameworks, comprehensive interviews, and validated rating scales to determine

the presence, severity, and specific subtype of the disorder. Accurate diagnosis is essential to distinguish major depressive disorder (MDD) from overlapping conditions and to guide appropriate, personalized treatment.

- **Standardized Diagnostic Criteria** The diagnosis of MDD is primarily governed by the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-10/ICD-11).^[6,13,34]
- **DSM-5 Criteria:** A diagnosis of MDD requires the presence of **five or more specific symptoms during the same consecutive two-week period**, representing a clear change from previous functioning.^[6,7] Crucially, at least one of these symptoms must be either a **depressed mood or anhedonia** (a markedly diminished interest or pleasure in almost all activities).^[6,7] Other qualifying symptoms include significant weight/appetite changes, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness or guilt, diminished concentration, and recurrent suicidal ideation.^[6]
- **ICD-10 Categorization:** The ICD-10 classifies depressive episodes based on symptom severity, categorizing them as **mild, moderate, or severe** (with or without psychotic symptoms).^[34]

Clinical Interviews (Gold Standards) Because relying solely on self-report questionnaires can lead to false positives-as patients may exhibit a wide range of neuropsychiatric symptoms like irritability, apathy, or emotional dysregulation that mimic depression-**clinical judgment via a structured interview by a trained clinician is strictly required**.^[4] The gold standard diagnostic interviews include:

- **Structured Clinical Interview for DSM (SCID):** A comprehensive diagnostic tool used to confirm MDD and exclude other Axis I disorders.^[4]
- **Mini-International Neuropsychiatric Interview (M.I.N.I.):** A brief structured clinical interview used to diagnose non-psychotic MDD and rule out conditions like bipolar disorder, current substance abuse, or psychotic features.^[1]
- **Composite International Diagnostic Interview (CIDI):** Often utilized in large-scale or epidemiological settings to estimate the prevalence of major depressive episodes.^[37]

Symptom Severity and Treatment Monitoring Scales Once a diagnosis is confirmed, clinicians use rating scales to establish baseline severity and measure treatment response.

Clinician-Administered Scales

- **Hamilton Depression Rating Scale (HDRS or HAM-D):** One of the most widely used clinician-rated tools, commonly administered in its 17-item or 21-item versions to evaluate total depressive symptomatology.^[10] To avoid confounding treatment response with medication side effects (like SSRI-

induced sleep or gastrointestinal disturbances), clinicians may use the **HRSD-6**, a shorter version that zeroes in strictly on core depressive symptoms (depressed mood, guilt, work/activities, retardation, psychic anxiety, and somatic symptoms).^[1]

- **Montgomery-Asberg Depression Rating Scale (MADRS):** A 10-item diagnostic questionnaire highly sensitive to measuring changes in the severity of depressive episodes over the course of treatment.^[32]
 - **Clinical Global Impression (CGI):** A clinician-determined summary scale that assesses overall illness severity (CGI-S) and tracks clinical improvement (CGI-I).^[6]
- Self-Report Questionnaires:**
- **Patient Health Questionnaire-9 (PHQ-9):** A brief, 9-item scale directly mapped to DSM criteria, widely utilized in primary care and research to measure current depressive symptom severity.^[4]
 - **Beck Depression Inventory-II (BDI-II):** A 21-item questionnaire evaluating symptom severity over the past week.^[11,39]
 - **Quick Inventory of Depressive Symptomatology (QIDS-SR-16):** A 16-item self-report measure to track long-term symptom changes.^[32]
 - **Center for Epidemiological Studies-Depression (CES-D):** Often used as a continuous measure of depressive symptom severity in community and longitudinal studies.^[37]

Specialized Diagnostics for Specific Subtypes

- **Perinatal and Postmenopausal Depression:** The DSM-5-TR includes a "with peripartum onset" specifier for episodes emerging during pregnancy or within 4 weeks post-delivery.^[21] For midlife women, tools like the **Menopause Rating Scale (MRS)** are used to simultaneously capture the somatic, psychological, and urogenital symptoms

associated with menopause.^[30] Additionally, a menopause-specific depression measure, the **Menopausal D scale**, is currently undergoing validation to specifically identify and quantify mood disturbances related to perimenopausal hormonal fluctuations.^[30]

- **Premenstrual Dysphoric Disorder (PMDD):** A formal diagnosis of PMDD requires the presence of specific affective and somatic symptoms during the luteal phase that reliably remit during the follicular phase.^[5] **This diagnosis must be prospectively confirmed via daily charting** over at least two consecutive symptomatic cycles, typically using the **Daily Record of Severity of Problems (DRSP)** combined with the Carolina Premenstrual Assessment Scoring System (C-PASS).^[5]
- **Adolescent Depression:** Diagnostic tracking in adolescents often utilizes age-specific tools such as the Quick Inventory of Depressive Symptomatology, Adolescent Version (QIDS-A17-SR) alongside tools to measure comorbid anxiety, such as the Screen for Child Anxiety Related Disorders (SCARED).^[40]
- **Differential Diagnosis and Comorbidities**
Depression must be carefully distinguished from conditions with overlapping clinical features. In severe cases, the negative symptoms of schizophrenia (such as affective blunting and social withdrawal) can mimic depression, requiring careful review of the patient's symptom trajectory.^[13]

Because MDD frequently co-occurs with anxiety disorders, comprehensive clinical assessment often includes anxiety-specific scales such as the **Generalized Anxiety Disorder-7 (GAD-7)** or the **Beck Anxiety Inventory (BAI)** to properly map the patient's full psychological profile.^[4,11]

5. PHARMACOLOGICAL MANAGEMENT BEYOND SSRIS

Drug Class / Strategy	Key Agents	Mechanism of Action	Clinical Role & Advantages	Limitations & Safety
SSRIs	Fluoxetine, Sertraline, Citalopram, Escitalopram	Selectively inhibit the serotonin transporter (SERT), increasing synaptic serotonin. ^[4,10]	Standard first-line treatment for MDD, anxiety, OCD, and PTSD ^[10] . Generally safer than older classes.	Delayed onset (weeks). Side effects include sexual dysfunction, GI upset, emotional blunting, and QTc prolongation (esp. citalopram). ^[10,17]
SNRIs	Venlafaxine, Duloxetine, Desvenlafaxine	Block reuptake of both serotonin and norepinephrine. ^[12,41]	Effective first-line alternatives. Particularly useful for comorbid chronic pain or fibromyalgia. ^[14]	Associated with withdrawal/discontinuation syndromes, nausea, and potential blood pressure elevation. ^[14,17]
TCAs	Amitriptyline, Imipramine, Nortriptyline	Inhibit serotonin/norepinephrine reuptake, but also block histamine, muscarinic, and alpha-1 receptors. ^[12,41]	Effective for severe MDD and frequently used at low doses for chronic neuropathic or gastrointestinal pain. ^[14]	Heavy side effect burden limits use: severe sedation, weight gain, constipation, dry mouth, and cardiotoxicity in overdose. ^[14,17]

MAOIs	Tranylcypromine, Phenelzine	Inhibit monoamine oxidase enzymes, stopping degradation of serotonin, dopamine, and norepinephrine. ^[41]	Highly effective for atypical or severe treatment-resistant depression ^[42]	Rarely used due to severe interactions. Requires a strict low-tyramine diet to avoid hypertensive crisis, and risks serotonin syndrome ^[17,42] .
Atypical & Multimodal	Vortioxetine, Mirtazapine, Bupropion, Vilazodone	Diverse. Vortioxetine: SERT inhibitor + 5-HT receptor modulator. ^[20,43] Bupropion: NDRI. ^[41] Mirtazapine: NaSSA. ^[14]	Target specific symptoms. Vortioxetine: improves cognition. ^[20] Bupropion: treats apathy, lacks sexual side effects. ^[13] Mirtazapine: treats insomnia and anxiety. ^[14,42]	Bupropion: lowers seizure threshold. ^[4] Mirtazapine: heavy sedation and weight gain. ^[43]

6. NON-PHARMACOLOGICAL MANAGEMENT




Fig. 6.1: Non pharmacological managements.

7. EMERGING AND ADVANCED THERAPIES

7.1 Neuromodulation (ECT, rTMS, tDCS, DBS)

- Neuromodulation techniques, including non-invasive brain stimulation (NIBS) and targeted electrical stimulation, are increasingly utilized for treatment-resistant cases or when patients wish to avoid pharmacological side effects.
- Electroconvulsive Therapy (ECT):** ECT remains a highly effective intervention for severe depression. Recent neuroimaging studies consistently show that ECT induces significant increases in hippocampal

volume.^[1] However, it is important to note that these volumetric changes do not always correlate directly with the clinical improvement of depressive symptoms; rather, they appear to be more closely related to the cognitive side effects frequently experienced post-treatment.^[1]

- Repetitive Transcranial Magnetic Stimulation (rTMS):** rTMS uses electromagnetic pulses to modulate neuronal excitability and is FDA-cleared for treatment-resistant depression.^[21] Standard protocols target the left dorsolateral prefrontal cortex

(DLPFC) at 10 Hz, though newer neuroscience-informed accelerated protocols and theta burst stimulation are reducing required treatment times^[21]. **rTMS is particularly valuable in perinatal depression**, as it avoids the risks of fetal drug exposure and does not affect breast milk.^[21] Meta-analyses confirm its efficacy and safety in pregnant women, reporting no severe maternal or fetal adverse events.^[21]

- **Transcranial Direct Current Stimulation (tDCS):** tDCS applies a low-amplitude direct current to the scalp to modulate cortical excitability^[21]. It is generally well-tolerated, and **combining tDCS with antidepressant medications produces a significantly greater effect size than using antidepressants alone**.^[21] Pilot randomized controlled trials in pregnant women who declined pharmacotherapy have shown that tDCS can lead to significantly higher remission rates at 4 weeks postpartum with minimal transient side effects.^[21]
- **Deep Brain Stimulation (DBS):** While more invasive, DBS research is advancing through the use of computational neuroscience. Whole-brain modeling and dynamic sensitivity analysis are being used to simulate in silico perturbations, helping researchers define personalized strategies and identify optimal "sweet spots" (such as the subthalamic nucleus) to drive brain state transitions for therapeutic neuromodulation.^[3]

7.2 Psychedelic-Assisted Therapy

Psychedelic-assisted therapy is emerging as a novel paradigm, particularly for depression accompanied by existential distress.

Efficacy in Specific Populations: Clinical trials have demonstrated that **psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer**.^[31] Long-term follow-up studies of psilocybin-assisted psychotherapy confirm lasting benefits for both psychiatric and existential distress in this highly vulnerable population.^[3]

Mechanisms of Action: The neural mechanisms of psychedelics differ vastly from those of standard antidepressants. Research using whole-brain modeling indicates that **serotonergic psychedelics like psilocybin and LSD act by increasing whole-brain turbulent dynamics** and enhancing global integration across brain networks.^[3] Furthermore, receptor-informed network control theory links these compounds to a "flattening of the brain's control energy landscape," facilitating increased cognitive flexibility and a breakdown of the rigid intrinsic connectivity often seen in depressive states.^[3]

7.3 Artificial Intelligence (AI) in Depression Management

The integration of Artificial Intelligence and Machine Learning (ML) is transforming how clinicians predict treatment outcomes and track adverse events.

Predicting Treatment Response: AI models are being trained on complex neuroimaging data to forecast patient responses to therapies before they begin. For instance, **Support Vector Machine (SVM) classifiers analyzing whole-brain turbulence dynamics have successfully predicted which patients will respond to SSRIs** with a 71% Area Under the Curve (AUC) accuracy.^[3] Similarly, machine learning analyses of resting-state functional connectivity within the brain's salience network have been used to robustly predict individual placebo response.^[32]

Adverse Event Prediction and Pharmacovigilance: Machine learning algorithms, such as random forests and gradient boosting, are being employed to predict the likelihood of adverse drug events by analyzing over 100 baseline features (e.g., demographics, comorbidities, pharmacogenomics).^[21] Additionally, Natural Language Processing (NLP) of clinical notes is helping to detect under-documented side effects, such as emotional blunting or cognitive impairment, improving real-world safety surveillance.^[17]

7.4 Digital Therapeutics

While comprehensive data on standalone digital therapeutics is limited in the provided sources, the literature highlights a growing reliance on digital tools for continuous monitoring and integrated care.

Real-Time Data Collection: Wearable devices and ecological momentary assessments via mobile apps are being increasingly utilized to capture real-world physiological and patient-reported outcomes.^[17,33]

Integrated Support: Digital interventions (e.g., mobile apps and internet support systems) are frequently integrated into collaborative care models and resource utilization tracking, serving as accessible, self-help measures that complement pharmacological and psychotherapeutic treatments.^[8]

8. CHALLENGES AND FUTURE PERSPECTIVES

Treatment-Resistant Depression (TRD) Despite the availability of numerous antidepressants, a significant proportion of patients do not achieve adequate relief and develop TRD, defined as the failure to respond to at least two adequate trials of antidepressants from different pharmacological classes.^[6] Overcoming TRD remains a major clinical challenge, driving the development of rapid-acting, non-monoaminergic agents like esketamine and dextromethorphan-bupropion.^[6,21]

Personalized Medicine Because up to half of patients do not respond to their first antidepressant and frequently experience limiting side effects, there is a critical need to move away from current "trial-and-error" prescribing practices.^[40] The future of depression management relies on tailoring interventions to an individual's specific clinical, biological, and genetic profile to match them with the most effective and tolerable treatment.^[13,40]

Pharmacogenomics (PGx) PGx is a cornerstone of personalized psychiatry, utilizing genetic testing to identify variations in liver enzymes (such as *CYP2D6*, *CYP2C19*, and *CYP2B6*) that metabolize antidepressants.^[12] By applying guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC), clinicians can preemptively adjust doses or select alternative medications for patients who are ultra-rapid or poor metabolizers, thereby minimizing adverse events and improving remission rates.^[12] Large-scale initiatives, such as the PRESIDE trial, are currently evaluating the clinical and cost-effectiveness of implementing PGx-guided prescribing directly into primary care.^[8]

Artificial Intelligence (AI) AI and machine learning are emerging as powerful tools to enhance predictive precision in depression care. For example, Support Vector Machine (SVM) algorithms analyzing whole-brain turbulent dynamics via fMRI have successfully predicted individual patient responses to SSRI treatment with up to 71% accuracy.^[3] Furthermore, machine learning models that integrate electronic health records, pharmacogenomic data, and patient-reported outcomes are being developed to detect and predict the likelihood of complex adverse drug events before they occur.^[17]

Biomarkers The lack of reliable clinical biomarkers is a significant hurdle in predicting antidepressant efficacy^[10]. However, emerging research highlights several promising candidates:

- **Telomere Length (TL):** Longer pre-treatment peripheral blood mononuclear cell TL has been shown to moderately predict better responsiveness to SSRI therapy.^[10]
- **Neuroimaging:** Baseline hippocampal volume and its changes during treatment are being investigated for early detection of treatment efficacy.^[1]
- **Inflammatory Markers:** Non-specific inflammatory markers like C-reactive protein (CRP) are positively correlated with telomerase activity and may index inflammatory states linked to poor treatment response.^[10]

Need for Integrated Care Managing depression effectively requires integrated, multidisciplinary care models, particularly for the elderly and those with complex medical comorbidities^[40]. Collaborative care models-such as the SMaRT Oncology-2 trial, which partnered consulting psychiatrists and care managers with primary oncology teams-have proven superior to standard care in improving both depression and physical pain^[31]. A major future perspective involves overcoming communication barriers between general practitioners, psychiatrists, psychologists, and geriatricians to establish cohesive treatment pathways that combine pharmacological, psychological, and social support^[42].

9. CONCLUSION

Major Depressive Disorder (MDD) is a highly complex and heterogeneous syndrome, making the traditional reliance on Selective Serotonin Reuptake Inhibitor (SSRI) monotherapy increasingly inadequate. Up to half of patients fail to adequately respond to their initial antidepressant trial, and remission rates often remain as low as 30% to 37.5%. Furthermore, conventional monoaminergic antidepressants are limited by a significant therapeutic lag of several weeks and are frequently accompanied by burdensome adverse effects, including emotional blunting, persistent sexual dysfunction, sleep disturbances, and debilitating discontinuation syndromes upon cessation. These substantial clinical limitations, combined with the high global burden of treatment-resistant depression, underscore the urgent need to move beyond standard trial-and-error prescribing toward a more comprehensive, multimodal management paradigm. Optimizing the care of MDD requires a shift toward an integrated, biopsychosocial approach. The combination of advanced pharmacotherapy-utilizing novel multimodal agents, rapid-acting glutamatergic modulators (e.g., esketamine, dextromethorphan-bupropion), and neurosteroids-with evidence-based non-pharmacological treatments yields superior clinical outcomes. Integrating relapse-prevention cognitive behavioral therapy (RP-CBT) alongside antidepressant medication significantly reduces relapse rates and promotes long-term wellness. Furthermore, lifestyle interventions, such as exercise therapy, reduce metabolic stress and biological aging, demonstrating mental health improvements comparable to pharmacotherapy. For severe, treatment-resistant, or specific populations (such as pregnant women), non-invasive neuromodulation techniques like repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) offer robust alternatives that show enhanced efficacy when combined with antidepressants. Ultimately, synthesizing these therapies within collaborative care models-which partner consulting psychiatrists with primary care teams-has proven superior to usual care. The future of depression management lies in precision psychiatry and personalized medicine. A primary focus is the widespread clinical implementation of pharmacogenomics (PGx) to tailor antidepressant selection and dosing based on genetic variations in metabolic enzymes (such as *CYP2D6* and *CYP2C19*). Large-scale initiatives, such as the PRESIDE trial, are actively evaluating the clinical and cost-effectiveness of integrating PGx-guided prescribing directly into primary care settings. Additionally, the validation of predictive biomarkers is a critical future direction to avoid prolonged, ineffective medication trials. Emerging tools, including pre-treatment telomere length, serum Brain-Derived Neurotrophic Factor (BDNF) levels, and AI-driven fMRI assessments of whole-brain turbulent dynamics, show high accuracy in forecasting individual patient responses to SSRIs before treatment even begins. Finally, future research must prioritize long-term safety

surveillance utilizing global pharmacovigilance databases (e.g., WHO VigiBase) to better track persistent or late-onset adverse events like metabolic syndrome, post-SSRI sexual dysfunction, and complex drug-drug interactions. Continued exploration into drug repurposing-leveraging the anti-inflammatory and neuroprotective properties of existing psychotropic drugs-also holds immense potential for treating comorbid cognitive decline and inflammatory conditions.

10. REFERENCES

- Kamishikiryo, T., Itai, E., Mitsuyama, Y., Masuda, Y., Yamamoto, O., Tamura, T., ... & Okada, G., Relationship between hippocampal volume and treatment response before and after escitalopram administration in patients with depression. *Translational Psychiatry*, 2025; 16(1): 1.
- Tahiri, J., Mian, M., Aftan, F., Habbal, S., Salehi, F., Reddy, P. H., & Reddy, A. P., Serotonin in depression and Alzheimer's disease: Focus on SSRI's beneficial effects. *Ageing research reviews*, 2024; 101: 102537.
- Escrachs, A., Sanz Perl, Y., Fisher, P. M., Martínez-Molina, N., G-Guzman, E., Frokjaer, V. G., ... & Deco, G., Whole-brain turbulent dynamics predict responsiveness to pharmacological treatment in major depressive disorder. *Molecular psychiatry*, 2025; 30(3): 1069-1079.
- Burgess, J., Ismail, K., Raymont, V., Emsley, R., Beckley-Hoelscher, N., Wall, J., ... & STOP-D Trial Group Elliott Brent Holsgrove Daniel Holliman Damian Leung Shu-Jen Martyn Meredith Nair Akshay Novak Alex Okai David O'Brien Frazer Paul Judson Immanuel Parks Nicholas Taylor David Uff Chris Venkatesan Gayathri Wilson Mark, The clinical and cost-effectiveness of sertraline in preventing depression in adults following a traumatic brain injury (STOP-D): study protocol for a multi-centre randomised controlled trial. *Trials*, 2025; 26(1): 438.
- Sundström-Poromaa, I., & Comasco, E., New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder: I. Sundström-Poromaa, E. Comasco. *CNS drugs*, 2023; 37(5): 371-379.
- Maji, S., Mohapatra, D., Jena, M., Srinivasan, A., & Maiti, R., Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol. *BMJ open*, 2024; 14(4): e080500.
- Bostan, Z. Z., Şare Bulut, M., & Gezmen Karadağ, M., Can vitamin D reduce the need for SSRI by modulating serotonin synthesis?: A review of recent literature. *Current nutrition reports*, 2025; 14(1): 39.
- Saya, S., Chondros, P., Abela, A., Mihalopolous, C., Chatterton, M. L., Gunn, J., ... & Emery, J., The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care. *Trials*, 2023; 24(1): 342.
- Saya, S., Chondros, P., Abela, A., Mihalopolous, C., Chatterton, M. L., Gunn, J., ... & Emery, J., The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care. *Trials*, 2023; 24(1): 342.
- Rampersaud R, Wu GWY, Reus VI, Lin J, Blackburn EH, Epel ES, Hough CM, Mellon SH, Wolkowitz OM. Shorter telomere length predicts poor antidepressant response and poorer cardiometabolic indices in major depression. *Sci Rep*, 2023 Jun 23; 13(1): 10238. doi: 10.1038/s41598-023-35912-z. PMID: 37353495; PMCID: PMC10290110.
- Kinney KL, Burkhouse KL, Chang F, MacNamara A, Klumpp H, Phan KL. Neural mechanisms and predictors of SSRI and CBT treatment of anxiety: A randomized trial focused on emotion and cognitive processing. *J Anxiety Disord*, 2021 Aug; 82: 102449. doi: 10.1016/j.janxdis.2021.102449. Epub 2021 Jul 10. PMID: 34274600; PMCID: PMC8364887.
- Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Ruano G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. *Clin Pharmacol Ther*, 2023 Jul; 114(1): 51-68. doi: 10.1002/cpt.2903. Epub 2023 May 30. PMID: 37032427; PMCID: PMC10564324.
- Li W, Gao B, Liu Y, He W, Zha W, Du S, Zeng Y, Zhang Y. Antidepressant Augmentation of Antipsychotic Treatment in Schizophrenia: A Narrative Review. *Med Sci Monit*, 2026 Mar 23; 32: e951119. doi: 10.12659/MSM.951119. PMID: 41866780; PMCID: PMC13023229.
- Silberbauer LR, Reed MB, Gryglewski G, Murgaš M, Nics L, Godbersen GM, Stimpfl T, Hahn A, Hacker M, Lanzenberger R. Acute effects of selective serotonin reuptake inhibitors on cerebral glucose metabolism and blood flow. *Transl Psychiatry*, 2026 Feb 3; 16(1): 54. doi: 10.1038/s41398-026-03849-2. PMID: 41633980; PMCID: PMC12873367.
- Edinoff, A. N., Fort, J. M., Woo, J. J., Causey, C. D., Burroughs, C. R., Cornett, E. M., ... & Kaye, A. D., Selective serotonin reuptake inhibitors and clozapine: clinically relevant interactions and considerations. *Neurology international*, 2021; 13(3): 445-463.

16. Crossen MJ, Hernandez LL. Placental and fetal consequences of maternal selective serotonin reuptake inhibitor use: current evidence and unresolved questions. *Front Pharmacol*, 2026 Apr 10; 17: 1789010. doi: 10.3389/fphar.2026.1789010. PMID: 42038283; PMCID: PMC13105990.
17. Chan ACY. Safety Concerns, Mechanistic Pathways, and Knowledge Gaps in the Clinical Use of Selective Serotonin Reuptake Inhibitors. *Cureus*, 2026 Jan 3; 18(1): e100719. doi: 10.7759/cureus.100719. PMID: 41640943; PMCID: PMC12864535.
18. Xeni F, Marangoni C, Lin L, Robinson ESJ, Jackson MG. Conditioned versus innate effort-based tasks reveal divergence in antidepressant effect on motivational state in male mice. *Neuropsychopharmacology*, 2025 Oct; 50(11): 1732-1742. doi: 10.1038/s41386-025-02140-0. Epub 2025 Jun 3. PMID: 40456959; PMCID: PMC12436657.
19. Hanna-Jairala I, Drossman DA. Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When. *Am J Gastroenterol*, 2024 Jul 1; 119(7): 1272-1284. doi: 10.14309/ajg.0000000000002800. Epub 2024 Apr 9. PMID: 38595149; PMCID: PMC11208063.
20. Adamo D, Calabria E, Coppola N, Pecoraro G, Mignogna MD. Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update. *Ther Adv Psychopharmacol*, 2021 Sep 3; 11: 20451253211034320. doi: 10.1177/20451253211034320. PMID: 34497709; PMCID: PMC8419528.
21. Yoon, S., Treatment Strategies for Perinatal Depression Beyond Conventional Antidepressants: A Narrative Review. *Clinical and Experimental Obstetrics & Gynecology*, 2026; 53(1).
22. Stimpfl JN, Walkup JT, Robb AS, Alford AE, Stahl SM, McCracken JT, Stancil SL, Ramsey LB, Emslie GJ, Strawn JR. Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms. *J Child Adolesc Psychopharmacol*, 2025 Feb; 35(1): 3-22. doi: 10.1089/cap.2024.0099. Epub 2024 Oct 29. PMID: 39469761; PMCID: PMC11971562.
23. Baudat, M., de Kort, A. R., van den Hove, D. L., & Joosten, E. A., Early-life exposure to selective serotonin reuptake inhibitors: Long-term effects on pain and affective comorbidities. *European Journal of Neuroscience*, 2022; 55(1): 295-317.
24. Ampuero, E., Duarte, A., Flores, F. S., Soto, A. I., Pino, C., Silva, V., ... & Wyneken, U., The multifaceted effects of fluoxetine treatment on cognitive functions. *Frontiers in Pharmacology*, 2024; 15: 1412420.
25. Taher, I. A. A., Eldin, F. K., Eissa, M. W., Saleh, L. A., Mohammed, O. A., Doghish, A. S., & Abdel Kway, A. S., Effect of fluoxetine on organ dysfunction and mortality in severe sepsis. *Plos one*, 2026; 21(1): e0340669.
26. Foletto VS, da Rosa TF, Serafin MB, Hörner R. Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use. *Eur J Clin Pharmacol*, 2022 Oct; 78(10): 1601-1611. doi: 10.1007/s00228-022-03372-5. Epub 2022 Aug 9. PMID: 35943535; PMCID: PMC9360648.
27. Meikle CKS, Creedon JF, McCullumsmith C, Worth RG. SSRIs: Applications in inflammatory lung disease and implications for COVID-19. *Neuropsychopharmacol Rep*, 2021 Sep; 41(3): 325-335. doi: 10.1002/npr.2.12194. Epub 2021 Jul 13. PMID: 34254465; PMCID: PMC8411309.
28. Vilar-Pereira, G., Gibaldi, D., Castaño-Barrios, L., da Silva, A. A., Resende Pereira, I., Cruz Moreira, O., ... & Lannes-Vieira, J., The beneficial effect of fluoxetine on behavioral and cognitive changes in chronic experimental Chagas disease unveils the role of serotonin fueling astrocyte infection by *Trypanosoma cruzi*. *PLoS Neglected Tropical Diseases*, 2024; 18(5): e0012199.
29. Nakhaee, H., Zangiabadian, M., Bayati, R., Rahmanian, M., Ghaffari Jolfayi, A., & Rakhshanderou, S., The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis. *PLoS One*, 2022; 17(10): e0267423.
30. Mogallapu, R., Sarich, R., Chalia, A., Ang-Rabanes, M., Gibson, E., Sugnam, V., ... & krishna prasad Vudathaneni, V., Beyond selective serotonin reuptake inhibitor (SSRIs): exploring hormonal therapy for mood disorders in perimenopause and postmenopause. *Cureus*, 2025; 17(10).
31. Bates, N., Bello, J. K., Osazuwa-Peters, N., Sullivan, M. D., & Scherrer, J. F., Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer: Bates et al. *Current Treatment Options in Oncology*, 2022; 23(3): 348-358.
32. Handoko, K., Neppach, A., Snyder, I., Karim, H. T., Dombrovski, A. Y., & Peciña, M., Expectancy-mood neural dynamics predict mechanisms of short-and long-term antidepressant placebo effects. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 2025.
33. Lenze, E. J., Reiersen, A. M., Zorumski, C. F., & Santosh, P. J., Beyond “psychotropic”: repurposing psychiatric drugs for COVID-19, Alzheimer’s disease, and Cancer. *The Journal of clinical psychiatry*, 2023; 84(3): 22r14494.
34. Seifert, J., Maier, H. B., Führmann, F., Bleich, S., Stübner, S., Sieberer, M., ... & Reinhard, M. A., Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: results from the AMSP pharmacovigilance program from 2001–2017. *Journal of Neural Transmission*, 2022; 129(7): 925-944.
35. Kato, M., Ogata, H., Tahara, H., Shimamoto, A., Takekita, Y., Koshikawa, Y., ... & Kinoshita, T.,

- Multiple pre-treatment miRNAs levels in untreated major depressive disorder patients predict early response to antidepressants and interact with key pathways. *International journal of molecular sciences*, 2022; 23(7): 3873.
36. Ok L, Ohlund L, Inkster AM, Campbell KSJ, Peñaherrera MS, Brain U, Sleno L, Robinson WP, Barry A, Oberlander TF, Vaillancourt C. Effect of depression and serotonin reuptake inhibitors antidepressant treatment during pregnancy on protein expression in the human placenta: A quantitative proteomics analysis. *PLoS One*, 2025 Dec 11; 20(12): e0322090. doi: 10.1371/journal.pone.0322090. PMID: 41379876; PMCID: PMC12698013.
 37. Lohman MC, Fairchild AJ, Merchant AT. Antidepressant Use Partially Mediates the Association Between Depression and Risk of Falls and Fall Injuries Among Older Adults. *J Gerontol A Biol Sci Med Sci*, 2021 Aug 13; 76(9): e171-e178. doi: 10.1093/gerona/glaa253. PMID: 33017840; PMCID: PMC8361338.
 38. Mahmood R, Wallace V, Wiles N, Kessler D, Button KS, Fairchild G. The lived experience of withdrawal from Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants: A qualitative interview study. *Health Expect*, 2024 Feb; 27(1): e13966. doi: 10.1111/hex.13966. PMID: 39102706; PMCID: PMC10774987.
 39. Doring, N., Hwang, Y. I., Akpanekpo, E., Gullotta, M., Ton, B., Knight, L., ... & Butler, T. G., Predicting attrition of men with a history of violence from randomised clinical trials. *Trials*, 2023; 24(1): 740.
 40. Shields M, McAusland L, Heintz M, Rittenbach K, Tsuyuki R, Box A, Emery J, Zwicker J, Arnold P, Newton A, Bousman C. Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents (PGx-GAP): Study Protocol for a Randomized Controlled Trial. *J Pers Med*, 2026 Feb 22; 16(2): 125. doi: 10.3390/jpm16020125. PMID: 41745416; PMCID: PMC12941580.
 41. Özkaya Gül, S., & Aydemir, E., The use of selective serotonin reuptake inhibitor (SSRI) antidepressants in the treatment of lung cancer. *International Journal of Molecular Sciences*, 2025; 26(10): 4546.
 42. Kasper, S., Incalzi, R. A., Bozzali, M., Morgado, P., & Siwek, M., Managing depression in the elderly: real-world clinical considerations and perspectives. *International Clinical Psychopharmacology*, 2025; 40(6): 339.
 43. Ekhart, C., van Hunsel, F., van Puijenbroek, E., Chandler, R., Meldau, E. L., Taavola, H., & Norén, G. N., Post-marketing safety profile of vortioxetine using a cluster analysis and a disproportionality analysis of global adverse event reports. *Drug Safety*, 2022; 45(2): 145-153.